LoQus23 targets DNA damage repair pathways to treat Huntington's disease, focusing on mitigating neurodegeneration caused by DNA instability. The company's approach aims to enhance cellular repair mechanisms, potentially slowing disease progression and improving patient outcomes.
Funding
$67.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FCFounders
Product
Problem
Huntington's disease is characterized by neurodegeneration resulting from DNA instability and impaired DNA damage repair mechanisms. Current treatments do not directly address the underlying causes of this DNA instability, leaving a significant unmet need for therapies that can slow or halt disease progression.
Solution
LoQus23 Therapeutics is developing therapies that target DNA damage repair pathways to treat Huntington's disease. The company's approach focuses on enhancing cellular mechanisms responsible for repairing DNA damage, thereby mitigating the neurodegeneration associated with the disease. By stabilizing DNA, LoQus23 aims to slow the progression of Huntington's disease and improve outcomes for patients. The therapeutic strategy seeks to address the root cause of the disease at a molecular level.
Target Audience
The primary target audience includes patients diagnosed with Huntington's disease and the medical professionals who treat them, as well as researchers focused on neurodegenerative diseases.
Features
- Focus on enhancing DNA damage repair mechanisms within cells.
- Aims to stabilize DNA to reduce neurodegeneration.
- Development of therapies targeting the underlying causes of Huntington's disease.